Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Minimal myocardial damage during coronary intervention is associated with impaired outcome.

Simoons ML, van den Brand M, Lincoff M, Harrington R, van der Wieken R, Vahanian A, Rutsch W, Kootstra J, Boersma E, Califf RM, Topol E.

Eur Heart J. 1999 Aug;20(15):1112-9.

PMID:
10413641
2.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

4.

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML.

N Engl J Med. 1999 May 27;340(21):1623-9. Erratum in: N Engl J Med 1999 Aug 12;341(7):548.

5.

Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).

Islam MA, Blankenship JC, Balog C, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ; EPISTENT Investigators.

Am J Cardiol. 2002 Nov 1;90(9):916-21.

PMID:
12398954
6.

Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.

Pels K, Schröder J, Witzenbichler B, Müller D, Morguet A, Pauschinger M, Schultheiss HP, Arntz HR.

Eur J Emerg Med. 2008 Dec;15(6):324-9. doi: 10.1097/MEJ.0b013e3282fc7626.

PMID:
19078834
9.

Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.

Fuchs S, Kornowski R, Mehran R, Gruberg L, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB.

J Invasive Cardiol. 2000 Oct;12(10):497-501.

PMID:
11022207
11.

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ.

Circulation. 1998 May 19;97(19):1912-20.

12.
13.

Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).

Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, Stone GW.

Am J Cardiol. 2007 Apr 15;99(8):1055-61. Epub 2007 Mar 6.

PMID:
17437727
15.

Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.

Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, Blankenship JC, Kitt MM, Topol EJ.

J Am Coll Cardiol. 1999 Jan;33(1):88-96.

16.

Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure.

Gruberg L, Mehran R, Waksman R, Dangas G, Fuchs S, Wu H, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB.

Am J Cardiol. 2001 Jun 15;87(12):1356-60.

PMID:
11397353
17.

Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).

Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, et al.

J Am Coll Cardiol. 1995 Jun;25(7):1693-9.

18.

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

Gibson CM, Murphy SA, Marble SJ, Cohen DJ, Cohen EA, Lui HK, Young J Jr, Kitt MM, Lorenz TJ, Tcheng JE.

Am Heart J. 2002 Jan;143(1):106-10.

PMID:
11773919
19.

Abciximab improves 6-month clinical outcome after rescue coronary angioplasty.

Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, Grazia Delle Donne M, Caravelli P, Nardi C, Mariani M.

Am Heart J. 2002 Feb;143(2):334-41.

PMID:
11835040
20.

Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?

Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML.

Circulation. 2002 Feb 5;105(5):554-6.

Supplemental Content

Support Center